Stocks
GlaxoSmithKline (GSK) R&D/CAPEX US GAAP (year values) |
|||||||||
| 2021 | 2022 | 2022 | 2023 | 2023 | LTM ? | CAGR 5 years ? | |||
| R&D/CAPEX, % | 180.1% | 243.0% | 243.0% | 265.4% | 223.8% | 268.3% | |||
| Changes by years, y/y, % | 0pp | +63pp | 0pp | +22pp | -42pp | +0.6% | |||
GlaxoSmithKline. R&D/CAPEX, %
GlaxoSmithKline. R&D/CAPEX, changes, pp
GlaxoSmithKline (GSK) R&D/CAPEX US GAAP (quarter values) |
||||||||
| 2023Q2 | 2023Q3 | 2023Q4 | 2023Q4 | 2024Q1 | LTM ? | |||
| R&D/CAPEX, % | 250.7% | 316.9% | 261.7% | 261.7% | 243.9% | 268.3% | ||
| Changes by years, y/y, % | -41pp | +36pp | +22pp | +22pp | +6pp | |||
| Changes by quarters, q/q, % | 0pp | +66pp | -55pp | 0pp | -18pp | |||
